EA200101179A1 - Полиморфные модификации кристаллического (2-бензгидрил-1-азабицикло[2.2.2]окт-3-ил)-(5-изопропил-2-метоксибензил)-аммония хлорида в качестве антагонистов рецептора нейрокинина 1 (nk-1) - Google Patents

Полиморфные модификации кристаллического (2-бензгидрил-1-азабицикло[2.2.2]окт-3-ил)-(5-изопропил-2-метоксибензил)-аммония хлорида в качестве антагонистов рецептора нейрокинина 1 (nk-1)

Info

Publication number
EA200101179A1
EA200101179A1 EA200101179A EA200101179A EA200101179A1 EA 200101179 A1 EA200101179 A1 EA 200101179A1 EA 200101179 A EA200101179 A EA 200101179A EA 200101179 A EA200101179 A EA 200101179A EA 200101179 A1 EA200101179 A1 EA 200101179A1
Authority
EA
Eurasian Patent Office
Prior art keywords
benzhydryl
azabicyclo
methoxybenzyl
isopropyl
crystalline
Prior art date
Application number
EA200101179A
Other languages
English (en)
Other versions
EA004264B1 (ru
Inventor
Даглас Джон Мелдрам Аллен
Трой Энтони Апплтон
Майкл Джон Гамкоуски
Дейвид Джозеф Мьюэлбауэр
Тимоти Норрис
Original Assignee
Пфайзер Продактс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Продактс Инк. filed Critical Пфайзер Продактс Инк.
Publication of EA200101179A1 publication Critical patent/EA200101179A1/ru
Publication of EA004264B1 publication Critical patent/EA004264B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Две кристаллические полиморфные формы дигидрата дигидрохлорида (2-бензгидрил-1-азабицикло[2.2.2]октил-3-ил)-(5-изопропил-2-метоксибензил)-амина представляют собой форму I и форму II. Фармацевтическая композиция, содержащая, по меньшей мере, одну из этих полиморфных модификаций, имеет выгодную стабильность для приготовления препарата для лечения рвоты у пациентов, получающих химиотерапию. Введение этой фармацевтической композиции обычно пероральное, предпочтительно с помощью таблетки или капсулы, либо внутривенное. Также раскрыт способ получения форм I и II.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200101179A 1999-06-22 2000-06-06 Полиморфные модификации кристаллического (2-бензгидрил-1-азабицикло[2.2.2]окт-3-ил)-(5-изопропил-2-метоксибензил)аммония хлорида в качестве антагонистов рецептора нейрокинина 1 (nk-1) EA004264B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14023399P 1999-06-22 1999-06-22
PCT/IB2000/000756 WO2000078759A1 (en) 1999-06-22 2000-06-06 Polymorphs of crystalline (2-benzhydryl-1-azabicyclo[2,2,2]oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-ammoniumchloride as nk-1 receptor antagonists

Publications (2)

Publication Number Publication Date
EA200101179A1 true EA200101179A1 (ru) 2002-06-27
EA004264B1 EA004264B1 (ru) 2004-02-26

Family

ID=22490317

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200101179A EA004264B1 (ru) 1999-06-22 2000-06-06 Полиморфные модификации кристаллического (2-бензгидрил-1-азабицикло[2.2.2]окт-3-ил)-(5-изопропил-2-метоксибензил)аммония хлорида в качестве антагонистов рецептора нейрокинина 1 (nk-1)

Country Status (35)

Country Link
US (1) US6262067B1 (ru)
EP (1) EP1187834A1 (ru)
JP (1) JP2003502425A (ru)
KR (1) KR20020030280A (ru)
CN (1) CN1390216A (ru)
AP (1) AP2001002367A0 (ru)
AR (1) AR024411A1 (ru)
AU (1) AU767336B2 (ru)
BG (1) BG106205A (ru)
BR (1) BR0011835A (ru)
CA (1) CA2375265A1 (ru)
CO (1) CO5190663A1 (ru)
CZ (1) CZ20014458A3 (ru)
DZ (1) DZ3055A1 (ru)
EA (1) EA004264B1 (ru)
EC (1) ECSP003538A (ru)
EE (1) EE200100698A (ru)
HR (1) HRP20010920A2 (ru)
HU (1) HUP0201694A3 (ru)
IL (1) IL146410A0 (ru)
IS (1) IS6161A (ru)
MA (1) MA26744A1 (ru)
MX (1) MXPA02000033A (ru)
NO (1) NO20016187D0 (ru)
NZ (1) NZ515348A (ru)
OA (1) OA11952A (ru)
PA (1) PA8496701A1 (ru)
PE (1) PE20010322A1 (ru)
PL (1) PL352899A1 (ru)
SK (1) SK18672001A3 (ru)
TN (1) TNSN00137A1 (ru)
TR (1) TR200103688T2 (ru)
UY (1) UY26211A1 (ru)
WO (1) WO2000078759A1 (ru)
ZA (1) ZA200110387B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387925B1 (en) * 1999-06-01 2002-05-14 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions
US7683071B2 (en) * 2000-07-26 2010-03-23 Taro Pharmaceuticals Industries Ltd. Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
US6939873B2 (en) 2000-07-26 2005-09-06 Taro Pharmaceuticals Industries Limited Non-sedating barbituric acid derivatives
US6756379B2 (en) 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
EP1551846A1 (en) * 2002-10-04 2005-07-13 Merck Sharp & Dohme Ltd. Azabicyclic spiroether derivatives as receptor antagonists
EP1569627B1 (en) * 2002-12-11 2008-11-12 Taro Pharmaceutical Industries Ltd. Method of treating movement disorders using barbituric acid derivatives
WO2006003651A2 (en) * 2004-07-02 2006-01-12 Taro Pharmaceutical Industries, Ltd A process for preparing 1-methoxymethyl-5,5-diphenylbarbituric acid
WO2008066704A2 (en) * 2006-11-14 2008-06-05 Taro Pharmaceuticals North America, Inc. Method of improving bioavailability for non-sedating barbiturates
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
UA27776C2 (ru) * 1991-05-31 2000-10-16 Пфайзер Інк. Производные хинуклидина и их фармацевтически приемлемые соли, которые являются антагонистами вещества р у млекопитающих, фармацевтическая композиция, имеющая антагонистическое действие на вещество р у млекопитающих
ES2096312T3 (es) * 1992-11-12 1997-03-01 Pfizer Derivado de quinuclidina como antagonista de la sustancia p.
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis

Also Published As

Publication number Publication date
ECSP003538A (es) 2002-01-25
SK18672001A3 (sk) 2002-08-06
AU767336B2 (en) 2003-11-06
CO5190663A1 (es) 2002-08-29
HUP0201694A2 (en) 2002-09-28
WO2000078759A1 (en) 2000-12-28
CZ20014458A3 (cs) 2002-03-13
NO20016187L (no) 2001-12-18
NZ515348A (en) 2003-07-25
DZ3055A1 (fr) 2004-03-27
MA26744A1 (fr) 2004-12-20
HUP0201694A3 (en) 2002-10-28
PL352899A1 (en) 2003-09-22
EA004264B1 (ru) 2004-02-26
UY26211A1 (es) 2001-01-31
PA8496701A1 (es) 2002-07-30
AU4774500A (en) 2001-01-09
US6262067B1 (en) 2001-07-17
AR024411A1 (es) 2002-10-02
EP1187834A1 (en) 2002-03-20
CN1390216A (zh) 2003-01-08
IL146410A0 (en) 2002-07-25
HRP20010920A2 (en) 2003-02-28
TR200103688T2 (tr) 2002-12-23
EE200100698A (et) 2003-02-17
NO20016187D0 (no) 2001-12-18
AP2001002367A0 (en) 2001-12-31
ZA200110387B (en) 2002-12-19
MXPA02000033A (es) 2002-07-02
PE20010322A1 (es) 2001-03-14
CA2375265A1 (en) 2000-12-28
IS6161A (is) 2001-11-13
KR20020030280A (ko) 2002-04-24
TNSN00137A1 (fr) 2002-05-30
OA11952A (en) 2006-04-13
JP2003502425A (ja) 2003-01-21
BR0011835A (pt) 2002-03-05
BG106205A (bg) 2002-07-31

Similar Documents

Publication Publication Date Title
CA2078578A1 (en) Medical use for tachykinin antagonists
MY138086A (en) Novel urea derivative as vanilloid receptor-1 antagonist
CY1106802T1 (el) Ανασταλτικη της εκκρισης γαστρικου οξεος συνθεση
AU2001293233A1 (en) Aza heterocyclic derivatives and their therapeutic use
ATE519486T1 (de) Pharmazeutische zusammensetzung mit einem monoamin-neurotransmitter-wiederaufnahmehemmer und einem acetylcholinesterase-hemmer
CA2432578A1 (en) Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists
WO2001027111A3 (de) Bicyclische imidazo-3-yl-aminderivate
DK0734383T3 (da) Cykliske amidderivater som neurokinin-A-antagonister
WO2003053945A3 (en) Urea derivatives and their use as vanilloid receptor antagonists
EA200101179A1 (ru) Полиморфные модификации кристаллического (2-бензгидрил-1-азабицикло[2.2.2]окт-3-ил)-(5-изопропил-2-метоксибензил)-аммония хлорида в качестве антагонистов рецептора нейрокинина 1 (nk-1)
ATE352543T1 (de) Ein dioxino(2,3-g)chinolin-9-carbonsäure derivat als nk3 rezeptor antagonist
ATE151637T1 (de) Heterozyklische verbindungen
WO2001027110A3 (de) Am sechsring substituierte, bicyclische imidazo-3-yl-aminderivate
ATE268174T1 (de) Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen
YU242789A (en) New compound, 4-fluoro-2-//(4-metoxy-2-pyridin-yl)methylsulphinyl/-1h-benzimidazole and process for obtaining
EA200100982A1 (ru) Полиморфные модификации кристаллического цитрата (2-бензгидрил-1-азабицикло[2.2.2]окт-3-ил)-(5-изопропил-2-метоксибензил)-амина в качестве антагонистов рецепторов нейрокинина 1 (nk1)
TW200517127A (en) Novel composition
BG106180A (en) Pharmaceutical composition containing sibutramine and orlistat
ES2197781A1 (es) Composiciones farmaceuticas liquidas de base acuosa en forma de suspension para la administracion por via oral de ibuprofeno.
EA200101108A1 (ru) Полиморфные модификации кристаллического цитрата азабицикло[2.2.2]октан-3-амина и их фармацевтические композиции
AR036131A1 (es) Derivados de benzo (g) quinolina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la fabricacion de un medicamento
EP1172106A3 (en) Use of fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles as substance P receptor antagonists
GB1420976A (en) Pharmaceutical compositions for use in the treatment of certain respiratory diseases or conditions in prematurely born children
RU93058142A (ru) Производные хинолина, способ их получения, фармацевтическая композиция и способ лечения
SE8301530D0 (sv) Pharmaceutical compositions containing a dibenzocycloheptadiene anti-depressant and an ergot alkaloid

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU